PTEN expression in non small cell lung carcinoma based on digitized image analysis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• HER2-dependent signaling pathways are frequently dysregulated in non-small cell lung carcinoma (NSCLC).
• The tumor suppressor gene PTEN (phosphatase and tensin homolog) plays a crucial role in regulating the HER2/PI3K/Akt signaling pathway.
• PTEN's function is critical in cellular processes including proliferation, survival, and migration.

Purpose of the Study:

• To quantitatively evaluate PTEN protein expression in NSCLC tissues.
• To correlate PTEN expression levels with clinicopathological parameters in NSCLC patients.
• To investigate the prognostic significance of PTEN expression in NSCLC.

Main Methods:

• Immunohistochemistry (IHC) was employed to determine PTEN protein expression in 61 NSCLC paraffin-embedded tissue samples.
• Digital image analysis was utilized for quantitative assessment of PTEN staining intensity.
• Clinicopathological data were analyzed in conjunction with PTEN expression levels.

Main Results:

• Loss of PTEN expression was observed in 39.34% of cases, with low expression in 47.54% and overexpression in 13.12%.
• Multivariate analysis revealed that PTEN overexpression was significantly associated with a lower risk of developing metastases (p=0.05).
• PTEN deregulation appears to be a frequent event in NSCLC.

Conclusions:

• PTEN deregulation is a common genetic event in NSCLC and is linked to the metastatic process.
• Trastuzumab, by binding to the ErbB2 receptor, can stabilize and activate PTEN.
• Loss of PTEN expression may negatively impact treatment response rates in NSCLC patients, particularly those treated with HER2-targeted therapies.